`
`Petition for Inter Partes Review
`Of U.S. Patent 8,278,351
`Exhibit
`ENZYMOTEC - 1049
`
`
`
`4.
`
`As described in detail in Exhibit 2, I selected RP-HPLC, HPLC-MS/MS and Multiple Reaction
`
`Monitoring (MRM) to analyze the lipid fractions for the presence of phosphatidylcholine (PC)
`
`containing EPA at both sn-l and sn-2 positions (PC-EPA/EPA), phosphatidylcholine with EPA at the
`
`sn-1 position and DHA at the sn—2 position or vice versa (PC-EPA/DHA, PC-DHA/EPA), and
`
`phosphatidylcholine with DHA at both of the sn-1 and sn-2 positions (PC-DHA/DHA). PC-
`
`EPA/EPA and PC-DHA/DHA (99% pure, Sigma Aldrich MO, USA) were used as reference
`
`standards. It is important to use reference standards and positive controls to verify that the analytical
`
`procedures are working and will perform their intended purpose. It is especially important to optimize
`
`mass spectrometric parameters using reference compounds.
`
`PC-EPA/EPA has a predicted molecular weight of 825.6, PC-EPA/DHA has a predicted molecular
`
`weight of 851.6, and PC-DHA/DHA has a predicted molecular weight of 877.6. The structures of the
`
`substances with molecular mass 825.6, 851.6 and 877.6 were examined by the use of RP- HPLC-
`
`MS/MS. An Agilent technologies high end linear tandem mass spectrometer (Agilent 6460 triple
`
`Quad) was interfaced with RP-HPLC using ESI ionisation in positive mode. Product ion scans of the
`
`protonated parent molecular weights (826.6 and 878.6) were then taken up for the reference standards.
`
`These data were then used as a basis for selection of multiple reaction monitoring (MRM) transitions
`
`and reconstructed ion chromatograms from the transitions described in the following were taken up.
`
`The transitions were chosen to allow us to determine whether the lipid is a phospahtidylcholine species
`
`and whether both the Sn-l and Sn-2 positions on the phospholipid are occupied by either EPA or
`
`DHA.
`
`
`
`PL-Specaes
`
`
`
`
`
`
`m———
`
`
`Ififlfiflflm
`-——— ’
`
`
`lflmfifimfl
`
`
`
`
`
`Retentroaw time’“ Parent mass Loss off MR5}?
`ihfl+l]
`ED
`
`
`
`game>J>1>>
`
`MRM
`
`3
`
`*' HPLC-MSIMS system
`
`5.
`
`Use of single quadrupole MS showed that all samples (with the exception of the ethyl acetate
`
`extracts from E. pacifica) contained lipids that matched either the theoretical molecular weight ( PC-
`
`EPA/DHA) or both molecular and theoretical weight and the chromatographic retention time of
`
`000002
`
`000002
`
`
`
`reference standards ( PC-EPA/EPA, PC-DHA/DHA). The E. pacifica ethyl acetate fractions contained
`
`very little material. It is not unlikely that something has not worked according to the procedure during
`
`the extraction of the E. pacifica krill samples and it is doubtful that these samples were representative
`
`samples. This
`
`assumption is supported by the fact that ethanol extraction of the same sample type gave
`
`a much higher
`
`yield and that ethyl acetate extraction of the same type of sample but with E.Superba
`
`instead ofE. pacifica also gave a high yield. The extraction should have been repeated but there was
`
`not enough time for this. However, it is expected that if sufficient amount of material had been used
`
`for the analysis the three phospholipid species would have been present as they were in the E. pacifica
`
`ethanol fractions and in the E.Superba ethyl acetate fractions.
`
`All samples were analyzed with MRM on the triple quadrupole, the criteria for positive identification
`
`was a positive signal at the correct retention time for the different MRMs as shown in the Table below
`
`(e.g., for PC-EPA/EPA a positive signal was required for [825+l]—>184 and MRMl). Full results for
`
`all samples are shown in the following Table.
`
`Vitas
`
`Frac.
`
`MRM
` MRM
`MRM
`MRM
`
`
`
`
`MRMs
`
`
`
`1
`2
`3
`4
`
`
`
`
`
`Treatment
`
`
`
`[325—111—434
`
`
`
`
`PC-
`Conclusion
`PC-
`PC—
`PC-
`
`
`
`
`
`
`°C/min
`[851+H]—>184
`
`
`
`EPA/EPA EPA/DHA EPA/DHA DHA/DHA
`
`826—624
`852—»524
`852—)550
`878—»550
`
`
`Contains PC-EPA/EPA
`
`Contains PC-EPA/DHA
`YES
`YES
`YES
`YES
`YES
`
`Contains PC—DHA/DHA
` Contains PC-EPA/EPA
`Contains PC—EPA/DHA
`
`Contains PC—DHA/DHA
`
`Contains PC-EPA/EPA
`
`Contains PC-EPA/DHA
`
`Contains PC-DHA/DHA
`
`n.d. PC-EPA/EPA
`
`n.d. PC—EPA/DHA
`
`n.d. PC—DHA/DHA
`
`n.d. PC-EPA/EPA
`
`70/5
`NO
`NO
`NO
`NO
`NO
`NO
`n.d. PC-DHA/DHA
`
`
`
`
`YES
`
`YEs
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`NO
`
`NO
`
`NO
`
`NO
`
`YES
`
`YES
`
`YEs
`YES
`
`YES
`
`YES
`YES
`
`NO
`
`NO
`
`NO
`
`NO
`
`n.d. PC—EPA/DHA
`
`000003
`
`
`
`
`II
`
`none
`
`P308-2
`
`70/5
`
`II
`II
`
`125/15
`
`none
`
`000003
`
`
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`n.d. PC-EPA/EPA
`NO
`
`n.d. PC-EPA/DHA
`N0
`NO
`NO
`NO
`NO
`
`NO
`n.d. PC—DHA/DHA
`
`Contains PC-EPA/EPA
`
`Contains PC-EPA/DHA
`
`
`Contains PC-DHA/DHA
`
`Contains PC-EPA/EPA
`
`Contains PC-EPA/DHA
`
`Contains PC-DHA/DHA
`
` Contains PC-EPA/EPA
`
`Contains PC-EPA/DHA
`
`Contains PC-DHA/DHA
`
` Contains PC—EPA/EPA
`Contains PC-EPA/DHA
`
`Contains PC-DHA/DHA
`
` Contains PC-EPA/EPA
`Contains PC-EPA/DHA
`
`Contains PC-DHA/DHA
`
`Contains PC—EPA/EPA
`
`Contains PC—EPA/DHA
`
`Contains PC-DHA/DHA
`
` Contains PC-EPA/EPA
`Contains PC—EPA/DHA
`
`Contains PC-DHA/DHA
`
` Contains PC-EPA/EPA
`Contains PC-EPA/DHA
`
`Contains PC-DHA/DHA
`
` Contains PC-EPA/EPA
`Contains PC-EPA/DHA
`
`Contains PC—DHA/DHA
`
`Contains PC-EPA/EPA
`
`Contains PC-EPA/DHA
`
`YES
`YES
`YES
`YES
`YES
`YES
`Contains PC-DHA/DHA
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`P308-6
`
`P308-7
`
`IIb
`
`
`
`125/15
`
`110116
`
`P208-8
`
`IIa
`
`70/5
`
`P308-9
`
`125/15
`
`P308—
`
`10
`
`P308-
`
`1 1
`
`P308—
`
`12
`
`P308-
`
`13
`
`P308-
`
`14
`
`P308-
`15
`
`P308-
`16
`
`
`
`
`
`none
`
`70/5
`
`125/15
`
`n.a.
`
`n.a.
`
`n.a.
`
`n.a.
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`YES
`
`YES
`
`YES
`YES
`
`YES
`YES
`
`YES
`
`YES
`YES
`YES
`
`YES
`YES
`YES
`
`YES
`YES
`
`YES
`
`YES
`YES
`
`YES
`
`YES
`
`YES
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`YES
`
`000004
`
`000004
`
`
`
`6.
`
`In summary, these results demonstrate that each of the lipid fractions tested (with the exception
`
`of the ethyl acetate extracts from E. pacifica) contain the following phospholipid species: PC-
`
`EPA/EPA; PC-EPA/DHA; and PC-DHA/DHA.
`
`7.
`
`I further declare that all statement made herein of my own knowledge are true and that all
`
`statements made on information and belief are believed to be true; and further that these statements
`
`were made with the knowledge that willful false statements and the like so made are punishable by
`
`fine or imprisonment, or both, under section 1001 of title 18 of the United States Code, and that such
`
`willful false statements may jeopardize the validity of the application or any patent issued thereon.
`
`Respectfully submitted,
`
`fws gaudy»...
`
`Dr. Thomas Gundersen
`
`Date: October 4, 2011
`
`000005
`
`000005
`
`
`
`EXHIBIT 1
`
`000006
`
`000006
`
`
`
`CURRICULUM VITAE OF THOMAS E GUNDERSEN
`
`Personal
`
`Name: Thomas Erik Gundersen
`
`Born: August 4th 1967
`
`Address: Lillevannsveien 69B, 0788 Oslo
`
`Phone: +47 22 95 86 31/ +47 928 08 973
`
`E-mail: teg@vitas.no
`
`Marital status: Married, 3 children
`
`Education
`
`1990-1995: M.Sc. in Chemistry, majoring in Analytical Chemistry,
`University of Oslo. Title of thesis: Quantitative high performance liquid
`chromatographic determination of retinoids in human serum using on—line solid
`phase extraction and column switching. Rating 1.2 ( on a scale from 1-6 where
`l is best)
`
`2007 Dr. Philos ( PhD) at the Medical Faculty, University of Oslo. 8
`published articles. Title: "Development of ultra-sensitive chromatographic
`tools for high—throughput analysis of retinoids in biological samples "
`
`Trial lecture: Lipidomics — Recent technological developments and
`applications
`
`Relevant work experience
`
`01/01/ 1998 to 12/31/2001: Recruitment Fellow of the Norwegian Cancer Society at the
`Institute for Nutrition Research, University of Oslo.
`
`01/01/2002 to 12/31/2004 Research Fellow at the Institute for Nutrition Research, University
`of Oslo.
`
`01.01 .2005-Researcher at the Institute for Nutrition Research, University of Oslo.
`
`2002 - General manager of Vitas' s
`
`2007 — General Manager Bioindex as
`
`2008 — Senior Researcher at the Medical Faculty, University of Oslo ( 20 %)
`
`000007
`
`000007
`
`
`
`Courses:
`
`Course in Gas Chromatography, 1997 1 day
`
`Courses in HP- LC-Chemstation, 1998 1 day
`
`Courses Capillary electrophoresis, 1998 2 days
`
`Course LC-MS, 1999 1 day
`
`Course LC-MS, 2000, one day
`
`Courses in LC-MS/MS, 2005 3 days
`
`HSE Course for Directors, 2008 1 day
`
`GMP courses, one day in 2008
`
`Teaching and tutoring
`
`Supervisor for graduate students Sakhi Amrit K, Stein Joakim Thommesen and Erasmus
`exchange student Carsten Haas in the period 1998-2001.
`
`Supervisor for doctoral students Amrit K Sakhi and Olov Nordstrom in the period 2001-2003.
`
`Supervisor for doctoral students Bente Lise Halvorsen and Anette Karlsen in the period
`2002—2008.
`
`The head of the analytical "subgroup" consisting of a total of 5 persons in Rune Blomhofl‘s
`research group at the Institute for Nutrition Research, University of Oslo. In the period 2000-
`2006
`
`Assistant supervisor for Post-Doc Sakhi Amrit K. and E. Nasser Bastani Fellow during 2008.
`
`Invited work
`
`a) Review, Gundersen, TE & Blomhoff, R., On-line solid-phase extraction and isocratic
`separation of retinoic acid isomers in micro drilling column switching system. Methods
`Enzym012992430-41, 430-441 (1999).
`
`b) Review, Gundersen, TE & Blomhoff, R., Qualitative and Quantitative liquid
`chromatographic determination of natural retinoids in biological samples. J Chromatogr A.
`2001 November 1923, 935 (1—2) :13-43.
`
`c) Review, Gundersen, TE, Methods for Detecting and Identifying retinoids in tissue. J
`Neurobiol. 2006 June; 66 (7) :631-44.
`
`Other activities
`
`000008
`
`000008
`
`
`
`Founded in 1994 AS Vitas, together with Professor Rune Blomhoff and Professor Christian A
`Drevon. AS Vitas is GMP certified analytical CRO that offers services to Academia,
`Pharmaceutical and biotech industry, hospitals and the Norwegian primary health care. The
`company is located in Oslo Innovation Centre. The analysis methods used are a direct result
`of graduate and doctoral work of Thomas Gunderson.
`
`Thomas Gundersen have from 1994 until today been central in the daily operation and
`development of business strategy and analysis in AS Vitas, and is part owner of the company.
`CEO of AS Vitas, 1 February 2002 —
`
`Founded in December 2006 the company Bioindex AS together with the technology transfer
`office of UIO. Thomas Gunderson sat on the board of Bioindex AS start-up to September
`2007.
`Is now CEO of Bioindex AS.
`
`"Expert reviewer” of fat-soluble vitamins in Finland Labquality external quality assurance
`program from September 2009 -
`
`Principal Scientist in EU projects:
`
`1. Food4Me — 2011-2015
`
`2. EPIC—CVD - 2012—2016
`
`3. Nutri Tech - 2012-2016
`
`Publications
`
`1 Gundersen, T. E., Lundanes, E. & Blomhoff, R. J Chromatogr B.Biomed.Sci.Appl. 691,
`1943—1958 (1997).
`
`2. Holven, KB, Natarajan, V., Gundersen, TE., Moskaug, JO, Norum, KR & Blomhoff, R.
`Int. J Cancer 71, 654-659 (1997).
`
`3. Sakhi, AK, Gundersen, TE., Wolf, SM, Blomhoff, R. & Lundanes, E.. J Chromatogr. A
`828, 451-460 (1998).
`
`4. Christensen, EI, Moskaug, JO, Vorum, H., Jacobsen, C., Gundersen, TE., Nykjaer, A.,
`Blomhoff, R., J Am Soc Nephrol 10, 685-695 (1999).
`
`5 Gunderson, T. E. & Blomhoff, R. Methods Enzym012992430-41, 430-441 (1999).
`
`6. P. Molander, TE Gundersen, C. Haas, T. Greibrokk, R. Blomhoff, E. Lundanes, Journal
`of Chromatography A 847, No. 1-2, 25 1999 59-68
`
`7. P. Molander, SJ Thommesen, IA Bruheim, R. Trones, T. Greibrokk, E. Lundanes, TE
`Gundersen, HRC Journal of High Resolution Chromatography, 22, Nr. 9, September 1999,
`pages 490-494
`
`000009
`
`000009
`
`
`
`8. Ulven SM, Gundersen TE, Weedon MS, Landaas VO, Sakhi AK, Fromm SH, Geronimo
`BA, Moskaug JO, Blomhoff R, Dev Biol 2000 in April 1915, 220 (2) :3 79—91
`
`9. SM. Ulven, TE. Gundersen, AK. Sakhi, JC. Glover and R. Blomhoff, Dev Dyn. 2001
`November; 222 (3) :341-53.
`
`10. F. Hoover, TE Gundersen, SM Ulven, J. Micha Ille, S. Blanchet, R. Blomhoff and JC
`Glover, J Comp Neurol. 2001 in July 1930, 436 (3) :324-35
`
`11 TE Gundersen and R. Blomhoff, J. Chromatogr A. 2001 November 1923, 935 (l-2) :13-
`43
`
`12. Petrosian AM, Haroutounian JE, Gundersen TE, Blomhoff R, Fugelli K, Kanli H.
`Adv Exp With Biol. 2000; 483:453-60.
`
`l3. Capillary High—Performance Liquid Chromatographic determination of lutein and
`zeaxanthin in aqueous humor from a single mouse eye. Anette Karlsen, George Alexander;
`Rune Blomhoff and Thomas E Gundersen.
`l: J Chromatogr B analyte Technol BioMed
`Life Sci. 2003 in September 1925, 795 (1) 217-23.
`
`14. Identification of novel roles of the cytochrome P450 system in early embryo genesis,
`effects Wed vasculogenesis and retinoic acid homeostasis. Diana ME Otto, Colin J.
`Henderson, Diane Carrie, Megan Davey, Ralf H. Adams, Cheryl Tickle, Thomas E.
`Gundersen, Rune Blomhoff and Rolan Wolf. Mol Cell Biol. 2003 September; 23
`(17) :6103-16.
`
`15. Sakhi AK, Russnes KM, Smeland S, Blomhoff R, Gundersen TE., Simultaneous
`quantification of Reduced and oxidized glutathione in plasma needs something a two-
`dimensional chromatographic system with parallel Porous graphitized carbon columns
`coupled with fluorescence and coulometric electrochemical detection. J Chromatogr A. 2006
`February 3, 1104 (1-2) 2179—89.
`
`16. Karlsen A, Blomhoff R, Gundersen TE. High-throughput analysis of vitamin C in
`human plasma with the use of HPLC with monolithic column and UV detection. J
`Chromatogr B analyte Technol BioMed Life Sci. 2005 in September 1925, 824 (1-2) :132—8.
`
`17. Drevon CA, Henriksen HB, Sanderud M, Gundersen TE, Blomhoff R. Biological
`effects of vitamin K and concentration of vitamin K in Norwegian food. Tidsskr Nor
`Laegeforen. 2004 Jun 17; 124 (12) :1650-4. Review.
`
`18. Gundersen, TE., Methods for Detecting and Identifying retinoids in tissue. J Neurobiol.
`2006 June; 66 (7) 2631-44.
`
`0000010
`
`0000010
`
`
`
`19. Sakhi AK, Blomhoff R, Gundersen TE. Simultaneous and trace determination of the
`Reduced and oxidized glutathione in minute plasma samples needs something dual mode
`fluorescence detection and column switching high performance liquid chromatography. J
`Chromatogr A. 2007 February 1923; 1142 (2) :178-84
`
`20. Karlsen A, Blomhoff R, Gundersen TE.
`Stability of whole blood and plasma Ascorbic acid. Eur J Clin Nutr. 2007 Feb 7
`
`21. TE Gundersen, NE Bastani, R. Blomhoff: Quantitative high-throughput determination
`of endogenous retinoids in human plasma needs something triple-stage liquid chromatography
`/ tandem mass spectrometry.Rapid commun Mass Spectrom. 2007; 21 (7) :1176—86.
`
`22. Berhe N, Halvorsen BL, Gundersen TE, Myrvang B, Gundersen SG, Blomhoff R.
`Reduced serum concentration of retinol and alpha-Tocopherol and high concentration of
`hydroperoxides are Associated with community levels of S. mansoni infection and
`schistosomal periportal fibrosis in Ethiopian school children. Am J Trop With Hyg. 2007
`May; 76 (5) :943-9.
`
`23. Noble BR, Babiuk RP, Clugston R, Underhill TM, Sun H, Kawaguchi R, Walfish PG,
`Blomhoff R, Gundersen TE, Greer JJ. Mechanisms of action of the congenital diaphragmatic
`hernia-inducing teratogen nitrofen. Am J Physiol Lung Cell Mol Physiol. 2007 August 1917
`
`24. Katy Schmidt, Catherine Hughes, JA Chudek, Simon Goodyear, Richard Aspden,
`Richard Talbot, Thomas E. Gundersen, Rune Blomhoff, Colin Henderson, C. Roland Wolf
`and Cheryl] Tickle. Cholesterol metabolism: the main pathway acting downstream of
`cytochrome P450 oxidoreductase in skeletal development of the limb. Molecular and cellular
`Biology, March 9 2009.
`
`24. Kristoffer Strom and Thomas E. Gundersen, Ola Hansson, Stephanie Lucas, Celine
`Fernandez, Rune Blomhoff, and Cecilia Holm. Hormone-sensitive lipase (HSL) is Also a
`Retinyl ester hydrolase: evidence from mice lacking HSL. FASEB J. February 2009.
`
`25. Nasser Bastani, Thomas E. Gundersen and Rune Blomhoff. Determination of 8-epi
`PGF20L in human plasma, full blood, erythrocyte and urine needs something isotope dilution
`and triple-stage liquid chromatography / tandem mass spectrometry. Rapid commun Mass
`Spectrom. 2009 in August 1910, 23 (18) :2885-2890.
`
`26. Trygve Holmoy 12’ Stine Marit Moen 1’ Thomas E. Gundersen 3’ A Michael Holick
`January 4 Falch 5 Enrico Fainardi 6’ Massimiliano 6’ Ilaria Casetta 6. Vitamin D in
`cerebrospinal fluid from Patients with multiple sclerosis relapse and remission hum.
`Accepted by Multiple Sclerosis, February 2009, Published online September 2009.
`
`27. Jaensson-Gyllenback E, Kotarsky K, Zapata F, Persson EK, Gundersen TE, Blomhoff
`R, Agace W W. Bile retinoids imprint intestinal CD103 (+) dendritic cells with the ability two
`gene ratio gut-tropic T cells. Mucosal Immunol. Mucosal Immunol. 2011 Jul;4(4):43 8-47
`
`28. Holmey T, Lossius A, Gundersen TE, Moen SM, Castellazzi M, Fainardi E, Casetta I.
`Intrathecal levels of vitamin D and lgG in multiple sclerosis. Acta Neurol Scand. 2011 Jul 23
`
`0000011
`
`0000011
`
`
`
`Posters and oral presentations
`
`1 Gundersen, T and Blomhoff, R., Automated chromatographic determination of fat-soluble
`vitamins. Oral presentation, 13th Norwegian symposium in chromatography, 1996.
`
`2. Sakhi, AK, Gundersen TE, Ulven, SM, Blomhoff, R. & Lundanes, E Electrochemical
`detection of endogenous retinoids in mouse embryos by HPLC with on-line solid-phase
`extraction and column-switching, Posters, HPLC 9, St. Louis, USA 1998.
`
`3. Gundersen, TE, Ulven, SM, Blomhoff, R., Ultra Sensitive screening of retinoids in
`embryonic minute samples, items, retinoids 99, Strasbourg, France. 1999.
`
`4. Gundersen, TE, Dahlgren, PA, Blomhoff, R., Peak Synchronised post-column injection of
`internal standards for correction of matrix ion suppression effects in electro spray ionisation.
`Poster, 23 rd Internatinal Symposium Wed chromatography, London, UK, 2000.
`
`5. Thomassen, A, Blomhoff, R, Gundersen, T., Transfer of chromatographic methods for
`routine determination of biological samples for capillary HPLC "plug & play"?, Oral
`presentation, 15th Norwegian symposium in chromatography, 2002.
`
`6 Sakhi, AK, Blomhoff, R, Gundersen, T., Isocratic RP-HPLC analysis of tocopherols and
`tocotrienols in plasma, Oral presentation, 15th Norwegian symposium in chromatography,
`2002.
`
`7 Gundersen, T and Blomhoff, R., Chromatographic determination of retinoids in embryonic
`tissue from mice. Oral presentation, 15th Norwegian symposium in chromatography, 2002.
`
`8. Gundersen TE, Invited plenary lecture “Kromatografidagene i Sandefjord”, January 2008.
`"High—throughput bioanalyse in routine. How to meet an increasing number of samples.
`
`9. Gundersen TE, Oral presentation MareLife March, Oslo Technopole 2009
`
`10. Gundersen TE, Oral Presentation, UCD Dublin, Human Nutrition: Where is the business?
`
`End.
`
`0000012
`
`0000012
`
`
`
`EXHIBIT 2
`
`0000013
`
`0000013
`
`
`
`Analytical Report
`
`Identification and Quantification of
`
`Specific Phospholipids in Krill Lipid
`
`Extracts by HPLC- Mass Spectrometry
`
`Sponsor: Aker Biomarine ASA
`
`Vitas project P308
`
`Sept 22-October 4th - 2011
`
`By:
`
`Dr. Thomas E. Gundersen
`
`CEO
`
`Anders Dahlgren, M.S.
`
`Laboratory Manager
`
`Vitas as, Oslo Innovation Centre, Norway
`
`Vitas P308 Page 1
`
`0000014
`
`
`
`AS Vitas project: P308/ F785, F788 and 789 Protocol ID 83
`
`Please refer to this for correspondence
`
`Receipt of Samples:
`Samples were sent by Nofima, Norway and received at AS Vitas 28. September and 30. September
`and In total 16 samples were received and then stored in fridge ( 5 °C) until analysis.
`
`Date of Analysis:
`The analysis of the samples took place between 28. September and 4. October 2011 in the
`laboratories of AS Vitas.
`
`Reference to Raw Data and Journal:
`
`The raw data and results are stored at as Vitas in the P308: project archive, Perm ID 135. The work
`
`details for the actual analysis were recorded in the laboratory notebook no. 53, starting at page 1.
`
`Archiving:
`Raw data from the analysis are recorded according to Vitas archiving policy.
`The data will be archived at Vitas as for 5 years after which as Vitas will contact the customer to
`agree on transfer, retention or destruction of data.
`
`Aim of the project
`The aim of the project (Vitas P308) was to identify, if present, three specific phophatidylcholine (PC)
`structures, carrying n3—PUFA fatty acids at both the Sn—1 and Sn—2 position, in different lipid extracts
`from krill. Combinations of different chromatographic and mass spectrometric techniques were
`used to investigate this.
`
`PC—EPA/DHA; and PC-DHA/DHA.
`
`Summary of findings
`In summary, these results demonstrate that each of the lipid fractions tested (with the exception of
`the ethyl acetate extracts from E. pacifica) contain the following phospholipid species: PC—EPA/EPA;
`
`mV
`
`itas as, Oslo Innovation Centre, Norway
`
`Vitas P308 Page 2
`
`0000015
`
`
`
`Introduction
`
`Vitas was asked to identify, if present, three specific phosphatidylcholine (PC) structures in
`
`different lipids extracts delivered to the Vitas laboratory in Oslo. In total 16 samples were received
`
`and registered in the Vitas database as shipment F785, F788 and 789 under Vitas project P308. An
`
`overview of the received samples is shown in table 1.
`
`Table 1 Overview of the received samples and specification of pre-analytical heat treatment
`
`Fraction
`
`Temperature treatment
`
`Marking of sample
`
`(“CI
`
`E. pacifica Fraction Ila not heated
`
`E. pacifica Fraction Ila 70 degr 5 min
`
`9.4 U1
`
`E. pacifica Fraction Ila 125 degr 15
`
`Taiyo E. superba ETOH extract
`
`U1
`
`I--‘ U'l
`
`U1
`
`I—-‘ U"
`
`E. pacifica Fraction Ilb not heated
`
`E. pacifica Fraction Ilb 7O degr 5 min
`
`E. pacifica Fraction Ilb 125 degr 15
`min
`
`E.Superba Fraction Ila not heated
`
`E.Superba Fraction Ila 70 degr 5 min
`
`E.Superba Fraction Ila 125 degr 15
`min
`
`\I
`
`I
`
`E.Superba Fraction Ilb not heated
`
`E.Superba Fraction Ilb 7O degr 5
`min
`
`H U'l
`
`E.Superba Fraction Ilb 125 degr 15
`min
`
`Vitas as, Oslo Innovation Centre, Norway
`
`Vitas P308 Page 3
`
`0000016
`
`
`
`Taiyo E. pacifica ETOH extract
`
`Taiyo E. pacifica crude PL extract
`
`Taiyo E. superba crude PL extract
`
`n.a. = not applicable
`
`The phophatidylcholines to be identified and quantified were to have omega-3 poly unsaturated
`
`fatty acids (n3—PUFA) in both Sn—l and Sn—2 position. The n3—PUFAS could be combination of the two
`n3—PUFAs A and B listed below.
`
`A. Eicosapentaenoic acid (EPA), 20:5(n-3), with IUPAC name: (52,82,112,142,17Z)—eicosa-5,8,11,14,17-
`
`pentenoic acid and a structure:
`
`
`
`Figure 1 EPA structure
`
`B. Docosahexaenoic acid (DHA), 22:6(n-3), with UIPAC name:
`
`(4Z,7Z,102,132,16Z,192)—docosa-
`
`4,7,10,13,16,19—hexaenoic acid and the structure;
`
`
`
`Figure 2 DHA structure
`
`Substituting the fatty acids A and B with the R in the generic phophatidylcholine structure below will
`
`give four possible structures. Three of these are listed in table 1. The forth structure is an isomeric
`structure of PC-EPA/DHA where EPA and DHA have changed place (PC—DHA/EPA). These two isomeric
`
`structures cannot easily be distinguished and nor is it relevant for the purpose of this examination to
`
`achieve this separation. Thus these isoform are treated as one in this study. PC—EPA/EPA
`
`and PC-DHA/DHA are available from commercial sources and pure reference substances of these
`
`were purchased and used in this study, PC—EPA/DHA are to our knowledge not commercially
`available.
`
`C. Generic structure of a phosphatidylcholine structure
`
`Vitas as, Oslo Innovation Centre, Norway
`
`Vitas P308 Page 4
`
`0000017
`
`
`
`
`
`Figure 3 Generic structure of a phosphatidylcholine molecule
`
`Table 2 Possible combination of DHA and EPA on a phophatidylcholine backbone, theoretical exact
`
`molecular weight (MW), observed MW of authentic reference standards and retention time in the
`
`described reversed phase chromatographic system. Molecular structures are shown in figure 4 and 5.
`
`PL—Species
`
`
`
`Retention
`Theoretical MW standard
`time
`MW
`By MS
`3.77 min
`.
`.
`PC-EPA/EPA
`
`_ PC-EF’A/DHA
`
`PCDHA/DHA
`
`*Elutes in between PC—EPA/EPA and PC—EPA/DHA
`
`O
`
`CH3
`HHCW—W—VW Cr}
`‘
`'
`o’\:/\o——P'-OV—w—CH3
`W6 O
`0H3
`
`H30 " _ ‘- ” ’—
`
`Figure 4 Molecular structure of PC—EPA/EPA (1,2-Dieicosapentaenoyl-sn-glycero-3-phosphocholine)
`
`
`
`Figure 5 Molecular structure of PC-DHA/DHA (1,2—Didocosahexaenoyl—sn—glycero-3—phosphocholine)
`
`Scientific approach
`
`The extracts to be examined contain a very complex mixture of lipids. Reversed phase liquid
`
`chromatography will be used to separate phospholipids from triacylglycerols, free fatty acids,
`
`Cholesterol esters and other lipids. The chromatographic step will also coarsely separate different
`
`species of phophatidylcholine to increase the sensitivity of the assay and reduce the risk of false
`
`positives.
`
`This chromatographic step will then be combined with different types of on—line mass spectrometry
`as described below.
`
`Vitas as, Oslo Innovation Centre, Norway
`
`Vitas P308 Page 5
`
`0000018
`
`
`
`Mass spectrometry (MS) and Tandem mass spectrometry (MS/MS). HPLC—MS will be used to develop
`
`the chromatographic method and to investigate the mass of the intact phospholipids and match
`
`these with reference standards. MS/MS, in the form of a triple quadrupole, will be used to perform
`
`product ion scans and multi reaction monitoring (MRM) on the intact phospholipids to further
`
`confirm the structure and identify the acyl groups attached to the lipid.
`
`Materials
`
`99 % pure PC—EPA/EPA (1,2—Dieicosapentaenoyl-sn-glycero-3-phosphocholine) and 99 % pure PC—
`
`DHA/DHA (1,2-Didocosahexaenoyl—sn-glycero-3-phosphocholine) were purchased from Sigma—Aldrich
`
`MO , USA. Dichloromethane, hexane, formic acid, ammonium formate, isopropanol and methanol
`
`were obtained from VWR Norway.
`
`Instrumentation
`
`LC—MS and MS/MS were delivered by Agilent technologies, Palo Alto, California, USA.
`
`Pre analytical heat treatment
`
`Heat treatment of samples were performed at 70 °C and 125 °C. Both treatments were performed by
`
`placing a suitable heat block inside the oven of a gas chromatograph, set to the either 70°C or
`
`125°C,
`
`for at least one hour. The sample vials were then heated for the required time, allowed
`
`cooling to room temperature standing on the laboratory bench, before analysis by HPLC—Mass
`spectrometry.
`
`Sample pre treatment
`
`For Vitas lD P308 1—3 and 7-9, both heat treated or non heat treated samples were dissolved in
`
`chloroform/methanol (2:1 v/v) concentration of approximately 30 mg/ml. For Vitas ID P308 4-6 and
`
`10-16, both heat treated or non heat treated samples were dissolved in chloroform/hexane (6:4 v/v)
`
`concentration of approximately 30 mg/ml. Samples were loaded into the automatic autosampler for
`
`HPLC—MS analysis.
`
`Reversed phase chromatography (RP-HPLC)
`
`RP—HPLC was performed with a Agilent technologies 1200 HPLC system using A: water
`
`/methanol/formic acid/ammonium formate ( 50015002121 v/v/v/w). B lsopropanol /formic
`
`acid/ammoniumformate(1000:1:1 v/v/w). Flow 0.6 ml/min. The separating column was a
`
`Phenomex Kinetic XB C-18, 150 mm x 4.6 mm id. ( 2.6 pm particles). The temperature on the
`
`column was 60 0C. A full description of this method is given in Appendix C.
`
`A representative chromatogram of a krill oil sample separated with this system is shown in Figure 6
`trace A and B.
`
` 'maxe”"fiilfiifimém'‘3‘“mammothbiafié’zfit-né-fififififiéidsoib)‘Esfififi'fl—' ""7 "
`I
`
`‘
`
`"
`
`"
`
`’ W
`
`ll lllll l
`
`.
`
`l 34
`
`
`
`1
`2
`3
`4
`.
`5
`e
`1
`a
`a
`mil 1
`
`
`
`
`Figure 6
`
`
`
`
`
`Vitas as, Oslo Innovation Centre, Norway
`
`0000019
`
`Vitas P308
`
`Page 1
`
`0000019
`
`
`
`Both traces are obtained using ESI ionisation in positive mode. Trace B shows the total ion
`
`chromatogram between m/z = 700—900. This will cover masses for PC-14:O—P16:1 to PC-DHA/DHA .
`Trace A shows the reconstructed ion chromatogram of m/Z = 184 from analysis of a krill oil sample.
`
`This ion is present in all phosphatidylcholines and illustrates that the chromatographic window contains the
`
`class of substances in question.
`
`
`'fisbimféfiiéivfifflcfibmwammraum'” ’1'1’022m’""fiffiméfimfizw-uéafi 183150027'Efiilij 25' "
`" ”
`
`St. PC-EPA/EPA m/z = 826
`3
`
`
`
`
`
`
`
`
`
`
`
`16 2 ' 4 a a , 10 12 , 14
`M501 S78, 3913717878] (CAPWKER BlelW’flE-AE um um 0910292011-03-3 13353200101013) ES
`
`__.
`
`; mi:
`
`
`
`3
`
`fL
`
`St. PC-DHA/DHA m/z = 878
`
`Figure 7
`
`Figure 7 shows selected ion monitoring (SIM) traces for the reference standard PC—EPA/EPA and PC-
`
`DHA/DHA, showing the retention time for the specific phospholipids and that these also are within
`
`the chromatographic window. The retention times can be found in table 3. A full description of the
`
`single quadrupole mass spectrometric conditions is given in Appendix C.
`
`Theoretical MW MWstandard Retentiontime Quantifier
`PL-Species
`
`
`PC—DHA/DHA
`
`PC—EPA/EPA
`PC—EPA/DHA
`
`219
`
`HPLC -Mass Spectrometry (MS)
`
`From the total ion chromatogram, masses for the three phospholipid combinations shown in table 3,
`
`were digitally extracted. The reconstructed ion chromatograms (RIC) are shown in figure 8.
`
`
`
`
`
`
`
`
`
`i§?33}: 6635113352: (TLBADNGR BIDMARW 1109M "mail/ER
`
`
`
`mimy
`m; C
`
`
`”SEEZE Etc-1325,7229: (5 LP
`
`
`
`
`EED
` a
`
`
`
`
`
`Figure 8
`
`m V
`
`itas as, Oslo Innovation Centre, Norway
`
`00020
`
`Vltas P308 Page 7
`
`0000020
`
`
`
`Trace A represents the TIC, trace B represents PC—DHA/DHA and trace C represents PC—DHA/EPA
`
`while trace D represents PC-EPA/EPA. It should be noted that there are only one narrow and
`
`symmetric peak in the entire chromatographic window for each trace. This indicates that there is
`
`probably only one phospholipid with this molecular weight in the sample. We also see that the
`
`retention time ofthese peaks matches perfectly the retention time of the reference standards (table
`
`1 and figure 7). For PC-EPA/DHA we do not have a reference standard but the sample contains a
`
`molecule that matches the theoretical molecular weight and that elutes in between the two others
`
`as anticipated.
`
`HPLC-MS/MS
`
`The structure of the substances with molecular mass 825.6, 851.6 and 877.6 were then further
`
`examined by the use of RP- HPLC—MS/MS. An Agilent Technologies high end linear tandem mass
`
`spectrometer (Agilent 6460 triple Quad) was interfaced with RP-HPLC using ESI ionisation in positive
`
`mode. Product ion scans of the protonated parent molecular weights (826.6 and 878.6) were then
`
`taken up using reference standards. Product ion scan for PC-EPA/EPA and PC—DHA/DHA (B) is shown
`
`in figure 9A and QB.
`
`x10 5 +ES| Product |on:4 (1.74 min) Frag=200.0V C|D@20.0 (8264 -> “) spa 510007.d
`
`
`
`.
`
`.
`
`.
`
`.
`
`~
`
`.
`
`.
`
`.
`
`7777777
`
`‘
`
`.
`
`171';§""A
`1.05
`.
`.
`1.025
`77777
`1
`.
`0.975
`.
`0.95
`0.925 .
`0.9
`0875
`0.85
`0825
`0.8
`0.775
`0.75 .
`0,725
`0.7
`0.675
`065 1
`0.625 3
`0.6 l
`0.575 ..
`0.55 ‘
`0525
`0.5
`0,475
`0.45
`0.425 W .
`0.4 .
`0375 ,
`0.35 .
`0.325 1
`0.3
`0.275
`0.25
`0,225
`0.2 77777777
`0175
`7777777
`015
`.
`..
`0.125 .
`0.1
`0.075
`0.05
`0.025
`0
`
`.
`..
`
`.
`.
`
`.
`
`, Plscan scan PC-EPA/EyPrAstandardm
`
` “”5 826.3
`
`
`
`5.42;... ,7
`
`if
`
`'9
`
`
`
`.
`
`
`
`.
`.
`..
`77777
`77777
`~
`777777
`~
`~ ...
`~ . ..
`~
`______.
`__
`100 125 150 175 200 225 250 275 300 325 350 375 400 425 450 475 500 525 550 575 500 625 050 075 700 725 750 775 300 825 850 875 900 925 950 975 1000
`Camus vs. MaSSJD—Chavge (mlz)
`
`Figure9A Product ion scan of PC-EPA/EPA
`
`Vitas as, Oslo Innovation Centre, Norway
`
`V1tas P308 Page 8
`
`0000021
`
`
`
`.. 6.6 . .,
`
`184.0
`
`.
`.
`.
`.
`,,,,,,,,,,
`
`.
`
`.
`
`.
`
`.
`
`777777777
`
`, W
`.
`
`.
`
`,,
`
`..
`..
`.,
`B753"
`’1 ’i’8783
`
`..
`
`
`. ~
`
`rrrrr
`
`.
`
`~77
`
`..
`
`.
`
`.
`
`.
`
`
`
`
`
`
`
`,4
`Il
`lrr
`llix
`
`no 5 +ESI Product lon:1 (2.04 min) Fraq=120.0V CID@20.0 [878.4 -> “) dha stDODZd
`7.4
`.,
`..
`,
`.
`,
`,
`72
`5,3
`7 ~ B
`6.4
`6.2
`5
`5.3
`.
`.,
`5.6
`5.4 m w
`5.2 mm
`5
`4.2
`4.6
`4.4
`4.2
`4
`3.8
`36
`34
`3.2
`3
`2.3
`2.6
`2.4
`2.2
`2
`1.8
`1.6
`1.4
`1.2
`1
`05
`0.6
`0.4
`0.2
`0
`
`
`100 125 150 175 200 225 20 275 300 325 350 375 400 475 450 475 500 525 550 575 600 625 650 675 700 725 750 775 300 325 350 B75 900 925 950 975 mm
`Counts vs. Mass-ID—Charge (mlz)
`
`Figure 98 Product ion scan of PC-DHA/DHA
`
`In figure 10 below the fragmentation pattern illustrated on the PC—EPA/EPA molecule is shown.
`
`If EPA from EPA/EPA
`
`
` m/z = 524.3
`
`Figure 10 Illustration explaining MS/MS fragmentation of phosphatidylcholine and rationale for
`selected MRMs.
`
`Vitas as, Oslo Innovation Centre, Norway
`
`Vitas P308 Page 9
`
`0000022
`
`
`
`Multiple Reaction Monitoring (MRM)
`
`In addition reconstructed ion chromatograms from the transitions described in table 4 below were
`
`taken up. The transitions were chosen to prove that that the lipid is a phospahtidylcholine species
`
`and that both the Sn—l and Sn-2 positions on the phospholipid is occupied by either EPA or DHA.
`
`Table 4 Overview of selected MRMs and retention times for the compounds in question
`
`
`
`
`PL-Species
`
`
`Retentiontime* Parentmass Lossoff MRM
`[M+1]
`ID
`827-6
`
`—*
`IE. PC-EPA/DHA
`852-6
`
`
`
`
`PC-EPA/DHA
`852-6
`
`
`3.94
`PC-DHA/DHA
`878-6 "I.
`
`
`* H PLC—MS/MS system
`
`
`
`
`
`
`
`Results
`
`HPLC-MS
`
`Use of single quadrupole MS showed that all samples (with the exception of the ethyl acetate
`
`extracts from E. pacifica) contained lipids that matched either the theoretical molecular